<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680130</article-id><article-id pub-id-type="doi">10.3390/vaccines12121358</article-id><article-id pub-id-type="publisher-id">vaccines-12-01358</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Longitudinal Immunological Analysis of Portuguese Healthcare Workers Across the COVID-19 Pandemic Reveals Differences in the Humoral Immune Response to Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vilela</surname><given-names>Lu&#x000ed;sa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01358" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Anabela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01358" ref-type="aff">1</xref><xref rid="fn1-vaccines-12-01358" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Cruz</surname><given-names>Alberta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01358" ref-type="aff">1</xref><xref rid="fn1-vaccines-12-01358" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Sousa</surname><given-names>Madalena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01358" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Margarida</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01358" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Fonseca</surname><given-names>Fernando</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af1-vaccines-12-01358" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Campino</surname><given-names>Susana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-vaccines-12-01358" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8985-9265</contrib-id><name><surname>Clark</surname><given-names>Taane G.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-vaccines-12-01358" ref-type="aff">2</xref><xref rid="af3-vaccines-12-01358" ref-type="aff">3</xref><xref rid="fn2-vaccines-12-01358" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Miranda</surname><given-names>Anabela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-vaccines-12-01358" ref-type="aff">4</xref><xref rid="c1-vaccines-12-01358" ref-type="corresp">*</xref><xref rid="fn2-vaccines-12-01358" ref-type="author-notes">&#x02021;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Plans-Rubi&#x000f3;</surname><given-names>Pedro</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01358"><label>1</label>Local Health Unit P&#x000f3;voa de Varzim/Vila do Conde, Largo da Miseric&#x000f3;rdia, 4490-421 P&#x000f3;voa de Varzim, Portugal</aff><aff id="af2-vaccines-12-01358"><label>2</label>Faculty of Infectious and Tropical Diseases, London School of Hygiene &#x00026; Tropical Medicine, Keppel Street, London WC1E 7HT, UK; <email>susana.campino@lshtm.ac.uk</email> (S.C.); <email>taane.clark@lshtm.ac.uk</email> (T.G.C.)</aff><aff id="af3-vaccines-12-01358"><label>3</label>Faculty of Epidemiology and Population Health, London School of Hygiene &#x00026; Tropical Medicine, Keppel Street, London WC1E 7HT, UK</aff><aff id="af4-vaccines-12-01358"><label>4</label>Department of Infectious Diseases, National Institute of Health Doctor Ricardo Jorge, Public Health Centre Doutor Gon&#x000e7;alves Ferreira, Rua Alexandre Herculano 321, 4000-055 Porto, Portugal</aff><author-notes><corresp id="c1-vaccines-12-01358"><label>*</label>Correspondence: <email>anabela.miranda@insa.min-saude.pt</email></corresp><fn id="fn1-vaccines-12-01358"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-vaccines-12-01358"><label>&#x02021;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1358</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> A vaccination programme against severe acute respiratory syndrome coronavirus 2 was initiated in Portugal in December 2020. In this study, we report the findings of a prospective cohort study implemented with the objective of monitoring antibody production in response to COVID-19 vaccination. <bold>Methods:</bold> The humoral immune response to vaccination was followed up using blood samples collected from 191 healthcare workers. Participants were split into three groups: the Oxford-AstraZeneca (Vaxzevria) vaccine group (<italic toggle="yes">n</italic> = 68), the Pfizer-BioNTech COVID-19 (Comirnaty) vaccine group (<italic toggle="yes">n</italic> = 51), and the Post-COVID group (<italic toggle="yes">n</italic> = 72). The kinetics of anti-spike antibody production were evaluated until 56 days on average after the third dose (booster). <bold>Results:</bold> We observed that antibody titres peaked approximately one month after full vaccination and declined steadily thereafter. We also found that mRNA vaccination induces higher titres of antibodies than viral vector vaccination, and both generate greater antibody responses than mild or moderate COVID-19. Additionally, whilst the booster for the Oxford-AstraZeneca and Pfizer-BioNTech groups led to antibody levels higher than those at any previous sample collection point, the booster for the Post-COVID group (persons with a history of COVID-19 prior to vaccination) led to antibody levels lower than those attained one month after the second dose. <bold>Interpretation:</bold> Our results indicate that there are different kinetics of antibody production between individuals who received the Pfizer-BioNtech mRNA vaccine and those who received the Oxford-AstraZeneca vector vaccine, or individuals who had COVID-19 before being vaccinated. Additionally, we observed that exposure to either natural infection or vaccination modulates the response to subsequent vaccination. This is particularly evident after administration of the third dose to the Post-COVID group, where our findings point to a hindrance in vaccine boosting, probably due to unwanted feedback by high titres of pre-existing antibodies.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>vaccines</kwd><kwd>booster</kwd><kwd>immunogenicity</kwd><kwd>antibody titre</kwd><kwd>prospective cohort study</kwd></kwd-group><funding-group><award-group><funding-source>Medical Research Council</funding-source><funding-source>National Institute for Health Research (NIHR)</funding-source><award-id>GEC2211</award-id><award-id>MR/V036890/1</award-id></award-group><award-group><funding-source>UKRI</funding-source><award-id>BBSRC BB/X018156/1</award-id><award-id>MRC MR/X005895/1</award-id><award-id>EPSRC EP/Y018842/1</award-id></award-group><funding-statement>TGC and SC were supported by the Medical Research Council and by the National Institute for Health Research (NIHR) (Ref. GEC2211, MR/V036890/1) using UK aid from the UK Government to support global health research. TGC and SC are funded by UKRI grants (BBSRC BB/X018156/1, MRC MR/X005895/1, EPSRC EP/Y018842/1). The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in writing the manuscript; or in the decision to publish the results.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01358"><title>1. Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel RNA coronavirus, was identified in early January 2020 as the cause of a pneumonia epidemic affecting the city of Wuhan, from where it spread across China, then to European countries, the USA, and the rest of the world. The World Health Organization (WHO) subsequently declared this a pandemic due to its widespread infectivity and high rate of transmission [<xref rid="B1-vaccines-12-01358" ref-type="bibr">1</xref>]. Early in the pandemic, efficacious vaccines were considered essential for preventing morbidity and mortality caused by COVID-19, and this drove notable advances in the development of new vaccines in a very short time. Less than one year after the SARS-CoV-2 genetic sequence was released by the Chinese Centre for Disease Control and Prevention, Pfizer-BioNtech, Moderna, and AstraZeneca-Oxford University published interim results on the safety and efficacy of their respective vaccines, and were granted emergency use authorisations in the USA, Europe, and elsewhere [<xref rid="B2-vaccines-12-01358" ref-type="bibr">2</xref>]. At the time, COVID-19 vaccines were first administered, only preliminary reports on clinical trials had been published. These studies assessed the safety, immunogenicity, and efficacy of both mRNA and viral vector vaccines, and concluded that both were safe, well-tolerated, and immunogenic, with efficacies ranging from 70% to 94%, depending on the vaccine type and manufacturer [<xref rid="B3-vaccines-12-01358" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01358" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01358" ref-type="bibr">5</xref>]. Nevertheless, further studies were needed to confirm these preliminary findings due to important limitations of the data.</p><p>At the beginning of December 2020, the Portuguese Government released the vaccination plan for COVID-19, which defined priority groups and respective stages of vaccination. In the first phase of the vaccine rollout, priority was given to people older than 50 years of age with long-term clinical conditions, residents in care homes, frontline health and social care workers, and security forces. The second and third phases of vaccination were applied successively to the remaining population according to age and associated pathologies [<xref rid="B6-vaccines-12-01358" ref-type="bibr">6</xref>]. Two types of vaccines were administered&#x02014;messenger RNA vaccines and viral vector vaccines. At this point in time, several key questions remained unanswered due to the short duration of follow-up studies [<xref rid="B3-vaccines-12-01358" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01358" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01358" ref-type="bibr">5</xref>]. Knowledge about the duration of SARS-CoV-2 antibodies elicited by vaccination was initially limited to a maximum of 57 days, reflecting the observation period reported in early clinical trial publications. Differences in antibody response induced by vaccines or natural COVID-19 disease were unknown, as were the responses after vaccination of na&#x000ef;ve versus Post-COVID recipients. There were also strategic considerations that could impact the success of vaccine programmes, logistical and biological, including vaccine transportation and storage, administration characteristics, and differences in underlying medical conditions of the general population compared to people in clinical trials [<xref rid="B7-vaccines-12-01358" ref-type="bibr">7</xref>]. Furthermore, as time progressed, it was important that the vaccine covered new variants. The continued emergence of new SARS-CoV-2 variants, particularly the Delta variant (B.1.617.2), caused sharp increases in infections worldwide, including countries with high vaccination coverage [<xref rid="B8-vaccines-12-01358" ref-type="bibr">8</xref>]. For this reason, the administration of a third dose of COVID-19 vaccine was recommended to address the potential waning of immunity over time and the reduced effectiveness of the vaccine against the Delta variant [<xref rid="B9-vaccines-12-01358" ref-type="bibr">9</xref>]. The European Medicines Agency (EMA) published its regulatory considerations on heterologous primary and booster COVID-19 vaccination in December 2021 based on evidence generated from short-term immunogenicity studies and a vaccine effectiveness study [<xref rid="B10-vaccines-12-01358" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01358" ref-type="bibr">11</xref>].</p><p>At the end of December 2020, the Local Health Unit P&#x000f3;voa de Varzim/Vila do Conde (HPVVC) started immunising health professionals, prioritised according to the risk of exposure. The vaccination schedules applied respected the rules defined by the General Directorate of Health for Portugal, which were as follows: COMIRNATY<sup>&#x000ae;</sup> vaccine&#x02014;two doses administered with an interval of 21 to 28 days; VAXZEVRIA<sup>&#x000ae;</sup> vaccine&#x02014;two doses administered 8 to 12 weeks apart; and for people who had COVID-19&#x02014;one dose of mRNA vaccine administered at least 3 months after recovery. To assess the longevity of the antibody response to vaccination, knowing that antibodies against other coronaviruses decrease over time (range: 12&#x02013;52 weeks from the onset of symptoms) [<xref rid="B12-vaccines-12-01358" ref-type="bibr">12</xref>], to compare the humoral immune response to the mRNA vaccine versus the viral vector vaccine, and to compare infection versus vaccination, we conducted a prospective cohort study (observational study) enrolling healthcare workers, both na&#x000ef;ve and previously infected. We report the quantity and duration of the humoral immune response after vaccination up to two months after the booster dose.</p></sec><sec id="sec2-vaccines-12-01358"><title>2. Materials and Methods</title><sec sec-type="subjects" id="sec2dot1-vaccines-12-01358"><title>2.1. Study Design and Participants</title><p>Anti-SARS-CoV-2-S RBD antibody levels were monitored over time using blood samples collected from 191 hospital workers vaccinated with the Pfizer-BioNTech COVID-19 (COMIRNATY) and the Oxford-AstraZeneca vaccines (Vaxzevria). The period of data collection spanned from January 2021 to March 2022. All participants volunteered and consented to take part in the study. Blood was drawn before administration of the first and second doses, and one month, four months, and eight months (only the Pfizer-BioNTech vaccine group) after full vaccination. At the end of 2021, the booster dose was administered, and the last evaluation took place two months later. Descriptions of the study&#x02019;s vaccine administration and follow-up are summarised in <xref rid="vaccines-12-01358-f001" ref-type="fig">Figure 1</xref> and <xref rid="app1-vaccines-12-01358" ref-type="app">Figure S1</xref>. All participants completed questionnaires at the time of blood sample collection, which included demographic information and previous history of COVID-19.</p></sec><sec id="sec2dot2-vaccines-12-01358"><title>2.2. Sample Processing and Analysis</title><p>Blood samples were collected in Sarstedt S-Monovette tubes, SARSTEDT AG &#x00026; Co. KG, N&#x000fc;mbrecht, Germany (order number 01.1602.001), and centrifuged at 3000 rpm for 10 min. Sera were transferred to new test tubes and underwent antibody testing. Antibodies directed at the spike protein of SARS-CoV-2 were measured at each timepoint using Roche Elecsys<sup>&#x000ae;</sup> anti-SARS-CoV-2 S kit, F. Hoffmann-La Roche Ltd, Basel, Switzerland (order number 09289267190), and Cobas e411 analyser F. Hoffmann-La Roche Ltd, Basel, Switzerland [<xref rid="B13-vaccines-12-01358" ref-type="bibr">13</xref>]. Elecsys<sup>&#x000ae;</sup> Anti-SARS-CoV-2 S is an electrochemiluminescence immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma. The assay uses a recombinant protein representing the RBD of the S antigen in a double-antigen sandwich assay format, which favours the detection of high-affinity antibodies against SARS-CoV-2. Samples with anti-SARS-CoV-2-S RBD concentrations above the measuring range (250 U/mL) were diluted automatically by the analyser with Diluent Universal, from 1:10 up to 1:100. After dilution by the analyser, the software automatically takes the dilution into account when calculating the sample concentration. Results were reported as concentrations (U/mL), with a cut-off of 0.8 U/mL or more considered positive.</p></sec><sec id="sec2dot3-vaccines-12-01358"><title>2.3. Statistical Analysis</title><p>The serological assay values were summarised using medians, ranges and geometric means. Differences across timepoints and vaccines were assessed using Kruskal&#x02013;Wallis and Wilcoxon non-parametric tests. Multiple linear regression analysis was further used on log transformed ratios of serological assay values to assess differences across vaccine groups and time adjusting for sex and age. A linear mixed model was applied to (log) antibody levels with fixed effects for age, gender, vaccine, time, and time&#x02013;vaccine interactions, with a random effect for participant. The R statistical analysis tool (v.4.4.1) was used to perform the analysis (R code may be made available upon request from the corresponding author). The baseline data were complete, and the statistical analyses were unaffected by missing data. Some participants were lost to follow-up, and were not replaced. We report the sample sizes across time, and adopted a complete case analysis approach.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01358"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-vaccines-12-01358"><title>3.1. Participants</title><p>Between January 2021 and March 2022, 191 healthcare workers were followed up after the first COVID-19 vaccination dose. The cohort included physicians, nurses, nurse aids, paramedical personnel, administrative, and logistic employees. The mean age at vaccination was 43 years (median: 42; range 20&#x02013;68 years). Most participants were female (160/191, 83,8%). Participants were split into three groups: Oxford-AstraZeneca (Vaxzevria) vaccine group (AZ: <italic toggle="yes">n</italic> = 68, 35.6%), Pfizer-BioNTech COVID-19 (COMIRNATY) vaccine group (Pfizer: <italic toggle="yes">n</italic> = 51, 26.7%), and Post-COVID group (<italic toggle="yes">n</italic> = 72, 37.7%) (<xref rid="vaccines-12-01358-t001" ref-type="table">Table 1</xref>). The age and sex distributions were similar across the three groups (Chi-squared test <italic toggle="yes">p</italic> &#x0003e; 0.2). The Post-COVID group received one dose of the Pfizer-BioNTech COVID-19 (COMIRNATY) vaccine ~six months after SARS-CoV-2 infection. This group consisted of nurses (22, 30.3%), healthcare assistants (17/72; 23.6%), medical doctors (16, 22.2%), and other health professionals (17, 23,6%). The main symptoms of this group were as follows: muscle pain (40/72), headache (38), loss of taste and smell (34), cough (26), fever (25), nausea (13), sore throat (12), and other (30).</p></sec><sec id="sec3dot2-vaccines-12-01358"><title>3.2. Concentration of Antibodies Against the SARS-CoV-2 Spike RBD over Time</title><p>The levels of antibodies were quantified at baseline (day of first dose = T0) and three weeks after the first vaccination for the Pfizer-BioNTech vaccine group (day of second dose = T1); at baseline (day of first dose = T0) and three months after the first vaccination for the AZ vaccine group (day of second dose = T1); at baseline (day of first dose = T0) for the Post-COVID group (only one dose); and during the respective follow-up (<xref rid="vaccines-12-01358-t001" ref-type="table">Table 1</xref>).</p><p>At baseline (T0), the median titre of antibodies against SARS-CoV-2 S-RBD was 0.4 UI/mL in both Pfizer and AZ groups; nevertheless, there were participants with evidence of previous asymptomatic infection (N with &#x0003e;0.8 UI/mL: Pfizer 4, AZ 8). The lowest antibody level in the Post-COVID group was 3.65 UI/mL, with all others &#x0003e;10 UI/mL. The median titre in the Post-COVID group was 97.9 UI/mL (IQR 46.79&#x02013;192.43), which is similar to the median titre observed at T1 (day the second vaccine dose) in the Pfizer (93.1) and AZ (72.6) groups.</p><p>The trends in the antibody levels against SARS-CoV-2 S-RBD during the follow-up period were similar amongst the groups. Namely, there was a spike in the immune response within one month of full vaccination, followed by a progressive decline, requiring a booster (<xref rid="vaccines-12-01358-t002" ref-type="table">Table 2</xref>; <xref rid="vaccines-12-01358-f002" ref-type="fig">Figure 2</xref>).</p><p>High titres of antibodies were detected one month after full vaccination (Tone: T1 + 1m) for the three groups, although statistically significant differences exist between them (median (IQR): Post-COVID 11,703 (9406&#x02013;21,368), AZ 1197 (592&#x02013;1964), Pfizer 2441 (1564&#x02013;4030)) (Kruskal&#x02013;Wallis test <italic toggle="yes">p</italic> &#x0003c; 2.2 &#x000d7; 10<sup>&#x02212;16</sup>). In particular, those in the Post-COVID group were the highest, 4.8 and 9.8 times higher than the medians of the Pfizer and AZ groups, respectively, whilst the levels in the Pfizer group were 2.0 times higher than those in the AZ group (Wilcoxon test <italic toggle="yes">p</italic>-value &#x0003c; 0.00002). Compared to baseline, the antibody levels at Tone were orders of magnitude greater, with the Post-COVID group having the least change due to already being exposed to the virus (T1 + 1M/T0 ratio median (IQR): AZ 2362 (645&#x02013;3741); Pfizer 5855 (3268&#x02013;8353); Post-COVID 129 (60&#x02013;222)) (Kruskal&#x02013;Wallis <italic toggle="yes">p</italic> &#x0003c; 2.2 &#x000d7; 10<sup>&#x02212;16</sup>). Antibody titres declined four months after the second dose (T1 + 4M) for all participants. The median antibody titre of the Pfizer group remained 2.3 times higher than that of the AZ group, whilst the Post-COVID group median titre was 3.6 and 8.4 times higher than that of Pfizer and AZ groups, respectively. Between T1 + 1M and T1 + 4M (i.e., ~3 months difference) there were decreases of ~60% in antibody levels, with Pfizer appearing to decrease the least (median: Pfizer 46%; AZ 60%; Post-COVID 65%) (Kruskal&#x02013;Wallis <italic toggle="yes">p</italic> = 0.0033) (<xref rid="vaccines-12-01358-t002" ref-type="table">Table 2</xref>; <xref rid="vaccines-12-01358-f002" ref-type="fig">Figure 2</xref>).</p><p>The decline in antibody levels was interrupted by the administration of the third dose. Unlike other timepoints, there was incomplete sampling at the booster timepoint (number with serology: AZ 40/68; Pfizer 32/51; Post-COVID 40/72). On average, 56 days after the booster (median (IQR) days: 56 (49&#x02013;70)), compared to the T1 + 4M timepoint, the booster median increases in antibody levels were 25-fold for AZ, 19-fold for Pfizer, and 2-fold for Post-COVID groups (<xref rid="vaccines-12-01358-t002" ref-type="table">Table 2</xref>; <xref rid="vaccines-12-01358-f002" ref-type="fig">Figure 2</xref>). Whilst both the boosters for the AZ and Pfizer groups led to antibody levels higher than those at any previous sample collection point (median (IQR): AZ 13,846 (9043&#x02013;24,555), Pfizer 25,000 (15,220&#x02013;25,000)), the booster for the Post-COVID group led to antibody levels lower than those at the T1 + 1M timepoint (median (IQR): 10,264 (6111&#x02013;15,552)). Notably, the Pfizer group levels were significantly higher (Wilcoxon <italic toggle="yes">p</italic> &#x0003c;0.0005). One participant did not respond to vaccination (in the AZ group with Pfizer booster). An estimated 12 participants contracted COVID-19 during the follow-up (Pfizer 3, AZ 7, Post-COVID 2), as detected by a sharp rise in antibody titre (<xref rid="vaccines-12-01358-f002" ref-type="fig">Figure 2</xref> and <xref rid="vaccines-12-01358-f003" ref-type="fig">Figure 3</xref>).</p><p>Using multivariate linear regression models, we considered the four common timepoints across each vaccine group (T0, T1 + 1M, T1 + 4M, Booster), and modelled the (log) ratio of the antibody levels relative to the T1 + 1M (<xref rid="vaccines-12-01358-t003" ref-type="table">Table 3</xref>). Consistently with the results above, the Post-COVID group had higher antibodies at the baseline (T0) ratio, and whilst the Pfizer group had higher nominal effects at T1 + 4M and booster timepoints, the ratios to Tone were similar between AZ and Pfizer groups (<italic toggle="yes">p</italic> &#x0003e; 0.03). Importantly, the Post-COVID group did not respond as well to the booster as the AZ and Pfizer groups (<italic toggle="yes">p</italic> &#x0003c; 0.001), which could point to antibody feedback (<xref rid="vaccines-12-01358-f003" ref-type="fig">Figure 3</xref>, <xref rid="vaccines-12-01358-t003" ref-type="table">Table 3</xref>). There were no strong effects of age (<italic toggle="yes">p</italic> &#x0003e; 0.39) or sex (<italic toggle="yes">p</italic> &#x0003e; 0.29) on the ratios.</p><p>A linear mixed model was applied to (log) antibody levels with fixed effects for age, gender, vaccine, time (4 common timepoints), and time&#x02013;vaccine interactions, with a random effect for the participants. Overall, there were significant time, vaccine, and vaccine-time interaction effects (all F-test <italic toggle="yes">p</italic> &#x0003c; 2 &#x000d7; 10<sup>&#x02212;16</sup>), but not for age (<italic toggle="yes">p</italic> = 0.11) or gender (0.93), all of which were consistent with previous analyses (<xref rid="vaccines-12-01358-t004" ref-type="table">Table 4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01358"><title>4. Discussion</title><p>Our study focused on the kinetics of the humoral immune response to COVID-19 vaccines in three different groups of healthcare workers. Two groups were composed of participants with no previous history of SARS-CoV-2 infection who were vaccinated with either two doses of Pfizer-BioNtech vaccine or two doses of Oxford-AstraZeneca vaccine. A third group was composed of participants previously infected with SARS-CoV-2 and vaccinated with one dose of Pfizer-BioNtech vaccine. All groups received a booster dose of the Pfizer-BioNtech vaccine.</p><p>When the first vaccine dose was given (T0), four volunteers in the Pfizer group and eight in the AZ group had antibody levels indicating prior infection with SARS-CoV-2. Since these participants stated in the vaccination survey that they had not previously contracted COVID-19, the infection was probably asymptomatic. During the post-vaccination monitoring period, three participants in the Pfizer group, seven in the AZ group, and two in the Post-COVID group experienced a sharp increase in antibody levels at T1 + 4 months after full vaccination, despite the expected decline in titres by this stage. Due to this, we concluded that these individuals were infected with SARS-CoV-2 post-vaccination, likely without symptoms as they did not disclose their condition during the booster appointment.</p><p>Our study was initially impacted by the emergence of the Alpha variant, followed by the Delta variant, and finally by the Omicron variant. The vaccines administered in the first, second, and third doses, designed for the original Wuhan strain of SARS-CoV-2, provided good protection against the disease caused by the variants that emerged up to Delta. Vaccination reduced the positivity duration and viral load in infected patients compared to unvaccinated patients. The illness was also reported to be mild [<xref rid="B14-vaccines-12-01358" ref-type="bibr">14</xref>]. Vaccine immune evasion and breakthrough infections became common due to the emergence of Omicron. The vaccine effectiveness was lower against this strain. Yet, the influence of the Omicron variant on our research was limited since it emerged towards the end of our observation period.</p><p>The kinetics of antibody production observed in our study, namely, high titres reached approximately one month after full vaccination followed by a progressive decline, are corroborated by findings reported in other studies. For example, one study found that total IgG anti-S protein responses assessed at different timepoints for three months in 871 participants vaccinated with two doses of Pfizer-BioNtech continuously increased, peaking after the second dose. Subsequently, a significant decrease occurred in the third month [<xref rid="B15-vaccines-12-01358" ref-type="bibr">15</xref>]. Similarly, a research conducted over six months found that the IgG produced in response to Pfizer-BioNtech peaked at two months and decreased over the next four months [<xref rid="B16-vaccines-12-01358" ref-type="bibr">16</xref>]. These observations were corroborated by several other similar investigations [<xref rid="B17-vaccines-12-01358" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01358" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-12-01358" ref-type="bibr">19</xref>]. The Oxford-AstraZeneca vaccine was also assessed in real-world studies, which revealed that following the second dose, IgG anti-S protein levels peaked after 21 days and gradually decreased thereafter. Nevertheless, IgG antibodies could be detected in the serum for up to six months [<xref rid="B20-vaccines-12-01358" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01358" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-01358" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01358" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01358" ref-type="bibr">24</xref>].</p><p>We also observed that peak antibody levels were higher following mRNA vaccination than following viral vector vaccination or natural infection, consistently with previous work [<xref rid="B25-vaccines-12-01358" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01358" ref-type="bibr">26</xref>]. In addition, homologous and heterologous vaccination schedules with Pfizer-BioNtech have been found to be more immunogenic than the homologous Oxford-AstraZeneca schedule. Also, no other immunisation plan generated neutralising antibodies greater than those induced by the homologous Pfizer-BioNTech schedule [<xref rid="B27-vaccines-12-01358" ref-type="bibr">27</xref>]. Another study analysed SARS-CoV-2-specific T cells and antibodies in transplant recipients and controls after homologous or heterologous vaccine regimens. Antibody titres in the control group were higher after mRNA vaccination, whereas the vector vaccine elicited greater numbers of T cells [<xref rid="B28-vaccines-12-01358" ref-type="bibr">28</xref>]. Additionally, we have shown that the initial antibody levels post-vaccination are much higher than those post-infection. A large-scale retrospective study following Pfizer-BioNtech mRNA vaccine administration also revealed that vaccinated individuals had higher antibody titres after the second dose than did convalescent individuals [<xref rid="B29-vaccines-12-01358" ref-type="bibr">29</xref>]. This observation confirmed findings from two small-scale studies that had reported initial antibody levels post-vaccination to be much higher than post infection [<xref rid="B30-vaccines-12-01358" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01358" ref-type="bibr">31</xref>].</p><p>Our results indicate that there are different kinetics of antibody production between individuals who received the Pfizer-BioNtech mRNA vaccine and those who received the Oxford-AstraZeneca vector vaccine, or individuals who had COVID-19 before being vaccinated with one dose of the Pfizer-BioNtech vaccine. The several classes of COVID-19 vaccines are different in their mode(s) of action, and in the way the spike antigen is presented to the immune system [<xref rid="B32-vaccines-12-01358" ref-type="bibr">32</xref>]. Pfizer-BioNtech and Oxford-AstraZeneca are mRNA and adenoviral vaccines, respectively, both of which provide genetic information for the biosynthesis of the spike protein (S) in body cells of vaccines [<xref rid="B33-vaccines-12-01358" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01358" ref-type="bibr">34</xref>]. These vaccines require that properly formed and folded S proteins are presented to B cells for the production of antibodies that successfully neutralise the virus [<xref rid="B32-vaccines-12-01358" ref-type="bibr">32</xref>]. Moreover, mRNA and adenovirus-vector vaccines stimulate different aspects of the immune response, particularly the innate immune response [<xref rid="B35-vaccines-12-01358" ref-type="bibr">35</xref>]. Variations in the biosynthesis of the S protein and antigen presentation may lead to differences in immunogenicity, as observed in our study.</p><p>Our work has shown that persons without a history of COVID-19 produce significantly lower antibody titres after the first and second doses of vaccination than individuals who were vaccinated after infection. Additionally, we observed that the booster administered ~10 months after the second dose led to an increase in antibody titres greater than the peak following initial vaccination in the Pfizer and AstraZeneca groups (immune-na&#x000ef;ve recipients). Findings from COV-BOOST, a randomised controlled trial that enrolled participants with no history of laboratory-confirmed SARS-CoV-2 infection, demonstrated that vaccines given as the third dose induced significantly higher anti-spike IgG levels at 28 days post boost than did the corresponding controls [<xref rid="B36-vaccines-12-01358" ref-type="bibr">36</xref>]. Similarly, another study showed that a third dose of Pfizer-BioNtech administered seven to eight months after the second dose resulted in an increase in neutralising antibodies greater than the peak following the primary two-dose series [<xref rid="B37-vaccines-12-01358" ref-type="bibr">37</xref>]. However, in our cohort, anti-spike antibody levels at approximately 2 months after the administration of the third dose did not increase as expected in individuals with a history of COVID-19 prior to vaccination (median increase from 4610 to 10,246 U/mL, the latter being lower than the median at T1 + 1m), although they increased substantially more in subjects without a history of COVID-19 (median increase from 550.8 to 13,846 U/mL in AZ group and median increase from 737.3 to 25,000 U/mL in Pfizer group). A recent study also revealed a much smaller increase in antibody levels after the third dose in persons with a history of COVID-19, although they continued to have significantly higher levels of anti-SARS-CoV-2 S antibodies than did those without a history of previous infection [<xref rid="B38-vaccines-12-01358" ref-type="bibr">38</xref>]. We hypothesise that the poor response after the booster in the Post-COVID group may be due to negative feedback from epitope masking, and/or antigen clearance at the site of vaccine injection caused by high levels of pre-existing antibodies. Overall, these findings indicate the modulation of the immune response to COVID-19 vaccines by previously elicited antibodies.</p><p>The immune response to an antigen results from various factors, among which the immunological memory of past exposures is included. It has been observed that antibody responses to malaria vaccines can be poor after repeated doses [<xref rid="B39-vaccines-12-01358" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-12-01358" ref-type="bibr">40</xref>]. The humoral immunity against the radiation-attenuated <italic toggle="yes">P. falciparum</italic> whole-sporozoite (PfSPZ) vaccine candidate in malaria-na&#x000ef;ve humans, studied by profiling B cell and antibody responses, showed that vaccine-specific antibodies increased and peaked after the first and second doses, but plateaued afterwards [<xref rid="B41-vaccines-12-01358" ref-type="bibr">41</xref>]. In addition, the expansion of specific B cells was lower after the third dose than after the second dose. Notably, subjects with high antibody titres at the time of the booster had poorer responses. These observations suggest that vaccine-induced antibodies bind epitopes masking them from B cell recognition, thus leading to the suppression of memory B cell responses [<xref rid="B41-vaccines-12-01358" ref-type="bibr">41</xref>].</p><p>Epitope masking has also been reported with seasonal and epidemic influenza vaccines. A mathematical model approach to investigate how pre-existing immunity affects the dynamics of antibody responses to influenza revealed that the masking of epitopes by antibody binding may play an important role in the dynamics of recall responses [<xref rid="B42-vaccines-12-01358" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-12-01358" ref-type="bibr">43</xref>]. In the presence of epitope masking, there is a decrease in the primary response and a much greater reduction in the boost following subsequent immunisation. This is because the masking effect is greater and the boost is smaller as the amount of antibody prior to immunisation increases. Conversely, in the absence of epitope masking, secondary immunisation results in an increase in antibody titres similar to that observed during the primary response, which is maintained for subsequent immunisations. These mathematical models were tested using published data from vaccination of humans with the 2012/2013 trivalent influenza vaccine [<xref rid="B44-vaccines-12-01358" ref-type="bibr">44</xref>]. Predictions of how pre-existing antibodies to influenza A hemagglutinin decrease the magnitude of the booster antibody response to this epitope following immunisation were confirmed.</p><p>Research indicating that prior immunity affects the immune response to COVID-19 vaccines emerged in late 2022, and early 2023. One study compared the antibody responses of Pfizer-BioNTech vaccine recipients following first, second, and third vaccine doses to the antibody responses of COVID-19 patients [<xref rid="B45-vaccines-12-01358" ref-type="bibr">45</xref>]. A significant feature was found that distinguishes the antibodies generated by vaccines from those generated after natural SARS-CoV-2 infection: vaccine-induced antibodies have &#x02018;breadth&#x02019; and can bind different viral variant spike proteins, whereas natural infection does not generate comparable breadth. Another important finding was the detection of the spike antigen, in 96% of vaccinees, in plasma collected 1&#x02013;2 days after the prime injection, with levels reaching as high as 174 pg/mL. However, the detection of the spike antigen in plasma samples ceased after the second dose of Pfizer-BioNtech vaccination, likely due to the formation of circulating immune complexes of anti-spike antibodies and spike protein. These complexes would mask antigen epitopes, preventing capture by detection antibodies, which is the basis of antigen detection assays. Similar assay interference has been reported for other diseases [<xref rid="B46-vaccines-12-01358" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-12-01358" ref-type="bibr">47</xref>]. Another study using preclinical SARS-CoV-2 mouse models demonstrated that previously elicited antibodies at low titres, or from broad multi-epitope responses, enhanced na&#x000ef;ve B cell recruitment to germinal centres. In contrast, high titres of high-affinity mono-epitope-specific antibodies limited the participation of cognate na&#x000ef;ve B cells. The directionality and intensity of this effect were determined by the antibody concentration, affinity, and epitope specificity of the primary response [<xref rid="B48-vaccines-12-01358" ref-type="bibr">48</xref>]. To study the influence of pre-existing antibodies in the development of memory B cells, researchers examined the memory B cell response in healthy individuals who received two high-affinity anti-SARS-CoV-2 monoclonal antibodies and, afterwards, two doses of an mRNA vaccine [<xref rid="B49-vaccines-12-01358" ref-type="bibr">49</xref>]. The results showed that pre-existing high-affinity antibodies can modify the antibody target profile, affinity, and isotype of the responding cells through two distinct mechanisms, one of which is direct masking of their cognate epitopes. Finally, a study of the anti-SARS-CoV-2 spike protein antibody responses in unexposed and exposed individuals revealed that lower antibody levels after the first dose were associated with a greater increase in antibody levels after the second dose, suggesting that pre-existing antibodies modulate the immunogenicity of mRNA vaccines [<xref rid="B50-vaccines-12-01358" ref-type="bibr">50</xref>]. In addition, mouse experiments have shown that pre-existing antibodies increase the clearance of vaccine antigens at the site of immunisation, limiting the amount of antigen available to prime B cell responses after mRNA boosters.</p><p>Reports of better antibody responses when the initial Pfizer-BioNTech doses are spaced at 12 weeks rather than at 3 weeks [<xref rid="B51-vaccines-12-01358" ref-type="bibr">51</xref>], and when people who are given initial Oxford-AstraZeneca doses spaced at 3&#x02013;4 weeks apparently have lower protection against infection than people who received the latter 16 weeks apart [<xref rid="B52-vaccines-12-01358" ref-type="bibr">52</xref>], are in agreement with the research mentioned above and may also be indicative of epitope masking leading to feedback inhibition.</p><p>To assess vaccine effectiveness in real-world settings is paramount. A multicentre study conducted in Europe during the autumn of 2023 estimated the COVID-19 vaccine effectiveness to be 40% overall against laboratory-confirmed symptomatic infections [<xref rid="B53-vaccines-12-01358" ref-type="bibr">53</xref>]. Another recent study reported a vaccine effectiveness of 60% against hospitalisation of persons with a positive test for SARS-CoV-2 who had received the last dose in the preceding three months. Vaccine effectiveness for severe disease was halved when the last vaccine dose had been administered in the preceding six months. As expected, vaccine effectiveness waned over time and was almost absent after six months [<xref rid="B54-vaccines-12-01358" ref-type="bibr">54</xref>].</p><p>The global SARS-CoV-2 test positivity reported to FluNet in October 2024 was 10.4% across 34 countries of the European Region. Over 312,000 new cases and 803 deaths were reported during the four-week period of the epidemiological update [<xref rid="B55-vaccines-12-01358" ref-type="bibr">55</xref>].</p><p>There are a few limitations of our study. First, the assay we used does not specifically measure neutralising antibodies. However, a high correlation was observed between a surrogate virus neutralisation assay and other assays, such as the Roche Elecsys<sup>&#x000ae;</sup>Anti-SARS-CoV-2 S assay [<xref rid="B56-vaccines-12-01358" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01358" ref-type="bibr">57</xref>]. Second, an additional limitation is that the assay uses a recombinant RBD protein for the in vitro quantitative determination of total antibodies in human serum and plasma, which favours the detection of high-affinity antibodies against SARS-CoV-2. Therefore, the Elecsys<sup>&#x000ae;</sup>Anti-SARS-CoV-2 S does not measure antibodies of greater breath directed at other epitopes of the spike protein, which may be produced if epitope masking by excess antibody occurs. Third, the age of the enrolled subjects ranges from 20 to 68 years, which corresponds to the working age of our study population composed of healthcare workers. Therefore, our work does not provide insights into immunity in children.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01358"><title>5. Conclusions</title><p>Our study showed that the highest antibody titres were reached approximately one month after full vaccination, and steadily declined thereafter. We also observed that mRNA vaccination induces higher titres of antibodies than viral vector vaccination, and both generate greater antibody responses than mild or moderate COVID-19. These observations are consistent with prior reports and point to differences in the immune responses induced by the Pfizer-BioNTech and Oxford-AstraZeneca vaccines as well as the disease. Additionally, we observed that whether initial exposure took place through natural infection or vaccines modulates the response to subsequent vaccination, particularly after the third dose. Our findings point to unwanted feedback where high titres of antibodies hinder vaccine boosting, possibly via epitope masking, as observed after repeated administration of the PfSPZ malaria vaccine.</p><p>As we are in the fourth year after the pandemic was declared, most of the world population has had several rounds of vaccination as well as the disease. The outcome of this study has implications for repeated rollout strategies even if they are adapted to new SARS-CoV-2 variants. This study has the potential to inform policy makers and national immunisation committees that need to establish vaccination criteria based on immunological considerations.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors want to thank all the study participants who volunteered to donate blood, and doing so contributed to improving the knowledge on COVID-19 vaccines. We also thank all nursing and other clinical staff for blood collection. The authors are extremely grateful to the senior management team at HPVVC for providing funding and infrastructure for sample collection and analysis, without which this study would not have been possible. In particular, we would like to express our gratitude to Joaquim Monteiro for the encouragement and praise we received throughout the study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01358"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="www.mdpi.com/article/10.3390/vaccines12121358/s1">www.mdpi.com/article/10.3390/vaccines12121358/s1</uri>. Figure S1. (A) Follow-up timeline after COVID-19 vaccination. T0 is baseline (first vaccination shot) and T1 is second vaccination shot; Pfizer and AZ groups. (B) Follow-up timeline after COVID-19 vaccination. T0 is baseline (first vaccination shot). Post-COVID-19 group. (C) SARS-CoV-2 variants across the study.</p><supplementary-material id="vaccines-12-01358-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01358-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualisation, A.M., L.V., S.C. and T.G.C.; formal analysis, A.M., T.G.C. and S.C.; funding acquisition S.C. and T.G.C.; investigation, L.V., A.S., A.C., M.S. and M.C.; resources, F.F.; software, T.G.C.; writing&#x02014;original draft preparation, A.M.; writing&#x02014;review and editing, A.M., T.G.C. and S.C.; supervision, A.M. A.M. was the chief investigator; A.S. and A.C. accessed and verified the underlying data. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Local Health Unit P&#x000f3;voa de Varzim/Vila do Conde (HPVVC) on the 15 Decembre 2020. The following national legislation and recommendations were also observed: Lei da Investiga&#x000e7;&#x000e3;o Cl&#x000ed;nica 21/2014 e 73/2015; Delibera&#x000e7;&#x000e3;o 1704/2015 da Comiss&#x000e3;o Nacional de Protec&#x000e7;&#x000e3;o de Dados.</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The study design is provided in the <xref rid="app1-vaccines-12-01358" ref-type="app">Supplementary Materials</xref>. Due to privacy restrictions, the datasets analysed during the current study will be made available from the corresponding author upon request, and after anonymization.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors declare no competing interests.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01358"><label>1.</label><element-citation publication-type="webpage"><article-title>WHO</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020" ext-link-type="uri">https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-03-11">(accessed on 11 March 2020)</date-in-citation></element-citation></ref><ref id="B2-vaccines-12-01358"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho</surname><given-names>T.</given-names></name>
<name><surname>Krammer</surname><given-names>F.</given-names></name>
<name><surname>Iwasaki</surname><given-names>A.</given-names></name>
</person-group><article-title>The First 12 Months of COVID-19: A Timeline of Immunological Insights</article-title><source>Nat. Rev. Immunology</source><year>2021</year><volume>21</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00522-1</pub-id><pub-id pub-id-type="pmid">33723416</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01358"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polack</surname><given-names>F.P.</given-names></name>
<name><surname>Thomas</surname><given-names>S.J.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Perez</surname><given-names>J.L.</given-names></name>
<name><surname>P&#x000e9;rez Marc</surname><given-names>G.</given-names></name>
<name><surname>Moreira</surname><given-names>E.D.</given-names></name>
<name><surname>Zerbini</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Safety and Efficacy of the BNT162b2 MRNA Covid-19; Vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01358"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Voysey</surname><given-names>M.</given-names></name>
<name><surname>Clemens</surname><given-names>S.A.C.</given-names></name>
<name><surname>Madhi</surname><given-names>S.A.</given-names></name>
<name><surname>Weckx</surname><given-names>L.Y.</given-names></name>
<name><surname>Folegatti</surname><given-names>P.M.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Angus</surname><given-names>B.</given-names></name>
<name><surname>Baillie</surname><given-names>V.L.</given-names></name>
<name><surname>Barnabas</surname><given-names>S.L.</given-names></name>
<name><surname>Bhorat</surname><given-names>Q.E.</given-names></name>
<etal/>
</person-group><article-title>Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01358"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baden</surname><given-names>L.R.</given-names></name>
<name><surname>El Sahly</surname><given-names>H.M.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Kotloff</surname><given-names>K.</given-names></name>
<name><surname>Frey</surname><given-names>S.</given-names></name>
<name><surname>Novak</surname><given-names>R.</given-names></name>
<name><surname>Diemert</surname><given-names>D.</given-names></name>
<name><surname>Spector</surname><given-names>S.A.</given-names></name>
<name><surname>Rouphael</surname><given-names>N.</given-names></name>
<name><surname>Creech</surname><given-names>C.B.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01358"><label>6.</label><element-citation publication-type="gov"><article-title>EPortugal</article-title><comment>Available online: <ext-link xlink:href="https://eportugal.gov.pt/en/noticias/plano-de-vacinacao-para-a-covid-19" ext-link-type="uri">https://eportugal.gov.pt/en/noticias/plano-de-vacinacao-para-a-covid-19</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-12-07">(accessed on 7 December 2020)</date-in-citation></element-citation></ref><ref id="B7-vaccines-12-01358"><label>7.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO Regional Office for Europe</collab>
</person-group><article-title>Strategic Considerations in Preparing for Deployment of COVID-19 Vaccine and Vaccination in the WHO European Region. Who/Euro:2020-1148-40894-55356</article-title><comment>Available online: <ext-link xlink:href="https://apps.who.int/iris/bitstream/handle/10665/335940/WHO-EURO2020-1148-40894-55356-eng.pdf?sequence=1&#x00026;isAllowed=y" ext-link-type="uri">https://apps.who.int/iris/bitstream/handle/10665/335940/WHO-EURO2020-1148-40894-55356-eng.pdf?sequence=1&#x00026;isAllowed=y</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-09">(accessed on 9 October 2020)</date-in-citation></element-citation></ref><ref id="B8-vaccines-12-01358"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pouwels</surname><given-names>K.B.</given-names></name>
<name><surname>Pritchard</surname><given-names>E.</given-names></name>
<name><surname>Matthews</surname><given-names>P.C.</given-names></name>
<name><surname>Stoesser</surname><given-names>N.</given-names></name>
<name><surname>Eyre</surname><given-names>D.W.</given-names></name>
<name><surname>Vihta</surname><given-names>K.-D.</given-names></name>
<name><surname>House</surname><given-names>T.</given-names></name>
<name><surname>Hay</surname><given-names>J.</given-names></name>
<name><surname>Bell</surname><given-names>J.I.</given-names></name>
<name><surname>Newton</surname><given-names>J.N.</given-names></name>
</person-group><article-title>Effect of Delta Variant on Viral Burden and Vaccine Effectiveness against New SARS-CoV-2 Infections in the UK</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>2127</fpage><lpage>2135</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01548-7</pub-id><pub-id pub-id-type="pmid">34650248</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01358"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barda</surname><given-names>N.</given-names></name>
<name><surname>Dagan</surname><given-names>N.</given-names></name>
<name><surname>Cohen</surname><given-names>C.</given-names></name>
<name><surname>Hern&#x000e1;n</surname><given-names>M.A.</given-names></name>
<name><surname>Lipsitch</surname><given-names>M.</given-names></name>
<name><surname>Kohane</surname><given-names>I.S.</given-names></name>
<name><surname>Reis</surname><given-names>B.Y.</given-names></name>
<name><surname>Balicer</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Effectiveness of a Third Dose of the BNT162b2 MRNA COVID-19 Vaccine for Preventing Severe Outcomes in Israel: An Observational Study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2093</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02249-2</pub-id><pub-id pub-id-type="pmid">34756184</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01358"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrews</surname><given-names>N.</given-names></name>
<name><surname>Stowe</surname><given-names>J.</given-names></name>
<name><surname>Kirsebom</surname><given-names>F.</given-names></name>
<name><surname>Toffa</surname><given-names>S.</given-names></name>
<name><surname>Sachdeva</surname><given-names>R.</given-names></name>
<name><surname>Gower</surname><given-names>C.</given-names></name>
<name><surname>Ramsay</surname><given-names>M.</given-names></name>
<name><surname>Lopez Bernal</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness of COVID-19 Booster Vaccines against COVID-19-Related Symptoms, Hospitalization and Death in England</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>831</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01699-1</pub-id><pub-id pub-id-type="pmid">35045566</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01358"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atmar</surname><given-names>R.L.</given-names></name>
<name><surname>Lyke</surname><given-names>K.E.</given-names></name>
<name><surname>Deming</surname><given-names>M.E.</given-names></name>
<name><surname>Jackson</surname><given-names>L.A.</given-names></name>
<name><surname>Branche</surname><given-names>A.R.</given-names></name>
<name><surname>El Sahly</surname><given-names>H.M.</given-names></name>
<name><surname>Rostad</surname><given-names>C.A.</given-names></name>
<name><surname>Martin</surname><given-names>J.M.</given-names></name>
<name><surname>Johnston</surname><given-names>C.</given-names></name>
<name><surname>Rupp</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>Homologous and Heterologous Covid-19 Booster Vaccinations</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>1046</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116414</pub-id><pub-id pub-id-type="pmid">35081293</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01358"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edridge</surname><given-names>A.W.D.</given-names></name>
<name><surname>Kaczorowska</surname><given-names>J.</given-names></name>
<name><surname>Hoste</surname><given-names>A.C.R.</given-names></name>
<name><surname>Bakker</surname><given-names>M.</given-names></name>
<name><surname>Klein</surname><given-names>M.</given-names></name>
<name><surname>Loens</surname><given-names>K.</given-names></name>
<name><surname>Jebbink</surname><given-names>M.F.</given-names></name>
<name><surname>Matser</surname><given-names>A.</given-names></name>
<name><surname>Kinsella</surname><given-names>C.M.</given-names></name>
<name><surname>Rueda</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Seasonal Coronavirus Protective Immunity Is Short-Lasting</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1691</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1083-1</pub-id><pub-id pub-id-type="pmid">32929268</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01358"><label>13.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Roche Diagnostics</collab>
</person-group><article-title>Elecsys&#x000ae; Anti-Sars-Cov-2 S Cobas</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/media/144037/download" ext-link-type="uri">https://www.fda.gov/media/144037/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-18">(accessed on 18 January 2021)</date-in-citation></element-citation></ref><ref id="B14-vaccines-12-01358"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lunt</surname><given-names>R.</given-names></name>
<name><surname>Quinot</surname><given-names>C.</given-names></name>
<name><surname>Kirsebom</surname><given-names>F.</given-names></name>
<name><surname>Andrews</surname><given-names>N.</given-names></name>
<name><surname>Skarnes</surname><given-names>C.</given-names></name>
<name><surname>Letley</surname><given-names>L.</given-names></name>
<name><surname>Haskins</surname><given-names>D.</given-names></name>
<name><surname>Angel</surname><given-names>C.</given-names></name>
<name><surname>Firminger</surname><given-names>S.</given-names></name>
<name><surname>Ratcliffe</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England</article-title><source>J. Infect.</source><year>2024</year><volume>88</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2023.10.016</pub-id><pub-id pub-id-type="pmid">37926118</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01358"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salvagno</surname><given-names>G.L.</given-names></name>
<name><surname>Henry</surname><given-names>B.M.</given-names></name>
<name><surname>Pighi</surname><given-names>L.</given-names></name>
<name><surname>De Nitto</surname><given-names>S.</given-names></name>
<name><surname>Gianfilippi</surname><given-names>G.L.</given-names></name>
<name><surname>Lippi</surname><given-names>G.</given-names></name>
</person-group><article-title>Waning Antibodies in SARS-CoV-2 Na&#x000ef;ve Vaccinees: Results of a Three-Month Interim Analysis of Ongoing Immunogenicity and Efficacy Surveillance of the MRNA-1273 Vaccine in Healthcare Workers</article-title><source>J. Infect.</source><year>2021</year><volume>83</volume><fpage>e4</fpage><lpage>e5</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2021.06.024</pub-id><pub-id pub-id-type="pmid">34214516</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01358"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponticelli</surname><given-names>D.</given-names></name>
<name><surname>Antonazzo</surname><given-names>I.C.</given-names></name>
<name><surname>Caci</surname><given-names>G.</given-names></name>
<name><surname>Vitale</surname><given-names>A.</given-names></name>
<name><surname>Della Ragione</surname><given-names>G.</given-names></name>
<name><surname>Romano</surname><given-names>M.L.</given-names></name>
<name><surname>Borrelli</surname><given-names>M.</given-names></name>
<name><surname>Schiavone</surname><given-names>B.</given-names></name>
<name><surname>Polosa</surname><given-names>R.</given-names></name>
<name><surname>Ferrara</surname><given-names>P.</given-names></name>
</person-group><article-title>Dynamics of Antibody Response to BNT162b2 MRNA COVID-19 Vaccine After 6 Months</article-title><source>J. Travel Med.</source><year>2021</year><volume>28</volume><fpage>taab173</fpage><pub-id pub-id-type="doi">10.1093/jtm/taab173</pub-id><pub-id pub-id-type="pmid">34697627</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01358"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Favresse</surname><given-names>J.</given-names></name>
<name><surname>Bayart</surname><given-names>J.L.</given-names></name>
<name><surname>Mullier</surname><given-names>F.</given-names></name>
<name><surname>Elsen</surname><given-names>M.</given-names></name>
<name><surname>Eucher</surname><given-names>C.</given-names></name>
<name><surname>Van Eeckhoudt</surname><given-names>S.</given-names></name>
<name><surname>Roy</surname><given-names>T.</given-names></name>
<name><surname>Wieers</surname><given-names>G.</given-names></name>
<name><surname>Laurent</surname><given-names>C.</given-names></name>
<name><surname>Dogn&#x000e9;</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Antibody Titres Decline 3-Month Post-Vaccination with BNT162b2</article-title><source>Emerg. Microbes Infect.</source><year>2021</year><volume>10</volume><fpage>1495</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1080/22221751.2021.1953403</pub-id><pub-id pub-id-type="pmid">34232116</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01358"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khoury</surname><given-names>J.</given-names></name>
<name><surname>Najjar-Debbiny</surname><given-names>R.</given-names></name>
<name><surname>Hanna</surname><given-names>A.</given-names></name>
<name><surname>Jabbour</surname><given-names>A.</given-names></name>
<name><surname>Abu Ahmad</surname><given-names>Y.</given-names></name>
<name><surname>Saffuri</surname><given-names>A.</given-names></name>
<name><surname>Abu-Sinni</surname><given-names>M.</given-names></name>
<name><surname>Shkeiri</surname><given-names>R.</given-names></name>
<name><surname>Elemy</surname><given-names>A.</given-names></name>
<name><surname>Hakim</surname><given-names>F.</given-names></name>
</person-group><article-title>COVID-19 Vaccine&#x02013;Long Term Immune Decline and Breakthrough Infections</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>6984</fpage><lpage>6989</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.10.038</pub-id><pub-id pub-id-type="pmid">34763949</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01358"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grupel</surname><given-names>D.</given-names></name>
<name><surname>Gazit</surname><given-names>S.</given-names></name>
<name><surname>Schreiber</surname><given-names>L.</given-names></name>
<name><surname>Nadler</surname><given-names>V.</given-names></name>
<name><surname>Wolf</surname><given-names>T.</given-names></name>
<name><surname>Lazar</surname><given-names>R.</given-names></name>
<name><surname>Supino-Rosin</surname><given-names>L.</given-names></name>
<name><surname>Perez</surname><given-names>G.</given-names></name>
<name><surname>Peretz</surname><given-names>A.</given-names></name>
<name><surname>Ben Tov</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Kinetics of SARS-CoV-2 Anti-S IgG after BNT162b2 Vaccination</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>5337</fpage><lpage>5340</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.08.025</pub-id><pub-id pub-id-type="pmid">34393018</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01358"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Pouwels</surname><given-names>K.B.</given-names></name>
<name><surname>Stoesser</surname><given-names>N.</given-names></name>
<name><surname>Matthews</surname><given-names>P.C.</given-names></name>
<name><surname>Diamond</surname><given-names>I.</given-names></name>
<name><surname>Studley</surname><given-names>R.</given-names></name>
<name><surname>Rourke</surname><given-names>E.</given-names></name>
<name><surname>Cook</surname><given-names>D.</given-names></name>
<name><surname>Bell</surname><given-names>J.I.</given-names></name>
<name><surname>Newton</surname><given-names>J.N.</given-names></name>
</person-group><article-title>Antibody Responses and Correlates of Protection in the General Population after Two Doses of the ChAdOx1 or BNT162b2 Vaccines</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1072</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01721-6</pub-id><pub-id pub-id-type="pmid">35165453</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01358"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shrotri</surname><given-names>M.</given-names></name>
<name><surname>Navaratnam</surname><given-names>A.M.D.</given-names></name>
<name><surname>Nguyen</surname><given-names>V.</given-names></name>
<name><surname>Byrne</surname><given-names>T.</given-names></name>
<name><surname>Geismar</surname><given-names>C.</given-names></name>
<name><surname>Fragaszy</surname><given-names>E.</given-names></name>
<name><surname>Beale</surname><given-names>S.</given-names></name>
<name><surname>Fong</surname><given-names>W.L.E.</given-names></name>
<name><surname>Patel</surname><given-names>P.</given-names></name>
<name><surname>Kovar</surname><given-names>J.</given-names></name>
</person-group><article-title>Spike-Antibody Waning after Second Dose of BNT162b2 or ChAdOx1</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>385</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01642-1</pub-id><pub-id pub-id-type="pmid">34274038</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01358"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robertson</surname><given-names>L.J.</given-names></name>
<name><surname>Price</surname><given-names>R.</given-names></name>
<name><surname>Moore</surname><given-names>J.S.</given-names></name>
<name><surname>Curry</surname><given-names>G.</given-names></name>
<name><surname>Farnan</surname><given-names>J.</given-names></name>
<name><surname>Black</surname><given-names>A.</given-names></name>
<name><surname>Blighe</surname><given-names>K.</given-names></name>
<name><surname>Nesbit</surname><given-names>M.A.</given-names></name>
<name><surname>McLaughlin</surname><given-names>J.A.D.</given-names></name>
<name><surname>Moore</surname><given-names>T.</given-names></name>
</person-group><article-title>IgG Antibody Production and Persistence to 6 Months Following SARS-CoV-2 Vaccination: A Northern Ireland Observational Study</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>2535</fpage><lpage>2539</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.02.087</pub-id><pub-id pub-id-type="pmid">35346536</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01358"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>S.K.</given-names></name>
<name><surname>Pradhan</surname><given-names>S.K.</given-names></name>
<name><surname>Pati</surname><given-names>S.</given-names></name>
<name><surname>Sahu</surname><given-names>S.</given-names></name>
<name><surname>Nanda</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Waning of Anti-Spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e19879</fpage><pub-id pub-id-type="doi">10.7759/cureus.19879</pub-id><pub-id pub-id-type="pmid">34976499</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01358"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhary</surname><given-names>H.R.</given-names></name>
<name><surname>Parai</surname><given-names>D.</given-names></name>
<name><surname>Chandra Dash</surname><given-names>G.</given-names></name>
<name><surname>Kshatri</surname><given-names>J.S.</given-names></name>
<name><surname>Mishra</surname><given-names>N.</given-names></name>
<name><surname>Choudhary</surname><given-names>P.K.</given-names></name>
<name><surname>Pattnaik</surname><given-names>D.</given-names></name>
<name><surname>Panigrahi</surname><given-names>K.</given-names></name>
<name><surname>Behera</surname><given-names>S.</given-names></name>
<name><surname>Ranjan Sahoo</surname><given-names>N.</given-names></name>
</person-group><article-title>Persistence of Antibodies against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>778129</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.778129</pub-id></element-citation></ref><ref id="B25-vaccines-12-01358"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramasamy</surname><given-names>M.N.</given-names></name>
<name><surname>Minassian</surname><given-names>A.M.</given-names></name>
<name><surname>Ewer</surname><given-names>K.J.</given-names></name>
<name><surname>Flaxman</surname><given-names>A.L.</given-names></name>
<name><surname>Folegatti</surname><given-names>P.M.</given-names></name>
<name><surname>Owens</surname><given-names>D.R.</given-names></name>
<name><surname>Voysey</surname><given-names>M.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Angus</surname><given-names>B.</given-names></name>
<name><surname>Babbage</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>1979</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmid">33220855</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01358"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walsh</surname><given-names>E.E.</given-names></name>
<name><surname>Frenck Jr</surname><given-names>R.W.</given-names></name>
<name><surname>Falsey</surname><given-names>A.R.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Neuzil</surname><given-names>K.</given-names></name>
<name><surname>Mulligan</surname><given-names>M.J.</given-names></name>
<name><surname>Bailey</surname><given-names>R.</given-names></name>
</person-group><article-title>Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmid">33053279</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01358"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Shaw</surname><given-names>R.H.</given-names></name>
<name><surname>Stuart</surname><given-names>A.S.V.</given-names></name>
<name><surname>Greenland</surname><given-names>M.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Andrews</surname><given-names>N.J.</given-names></name>
<name><surname>Cameron</surname><given-names>J.C.</given-names></name>
<name><surname>Charlton</surname><given-names>S.</given-names></name>
<name><surname>Clutterbuck</surname><given-names>E.A.</given-names></name>
<name><surname>Collins</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of Heterologous versus Homologous Prime-Boost Schedules with an Adenoviral Vectored and MRNA COVID-19 Vaccine (Com-COV): A Single-Blind, Randomised, Non-Inferiority Trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>856</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01694-9</pub-id><pub-id pub-id-type="pmid">34370971</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01358"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>T.</given-names></name>
<name><surname>Klemis</surname><given-names>V.</given-names></name>
<name><surname>Schub</surname><given-names>D.</given-names></name>
<name><surname>Schneitler</surname><given-names>S.</given-names></name>
<name><surname>Reichert</surname><given-names>M.C.</given-names></name>
<name><surname>Wilkens</surname><given-names>H.</given-names></name>
<name><surname>Sester</surname><given-names>U.</given-names></name>
<name><surname>Sester</surname><given-names>M.</given-names></name>
<name><surname>Mihm</surname><given-names>J.</given-names></name>
</person-group><article-title>Cellular Immunity Predominates over Humoral Immunity after Homologous and Heterologous MRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients</article-title><source>Am. J. Transplant.</source><year>2021</year><volume>21</volume><fpage>3990</fpage><lpage>4002</lpage><pub-id pub-id-type="doi">10.1111/ajt.16818</pub-id><pub-id pub-id-type="pmid">34453872</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01358"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Israel</surname><given-names>A.</given-names></name>
<name><surname>Shenhar</surname><given-names>Y.</given-names></name>
<name><surname>Green</surname><given-names>I.</given-names></name>
<name><surname>Merzon</surname><given-names>E.</given-names></name>
<name><surname>Golan-Cohen</surname><given-names>A.</given-names></name>
<name><surname>Sch&#x000e4;ffer</surname><given-names>A.A.</given-names></name>
<name><surname>Ruppin</surname><given-names>E.</given-names></name>
<name><surname>Vinker</surname><given-names>S.</given-names></name>
<name><surname>Magen</surname><given-names>E.</given-names></name>
</person-group><article-title>Large-Scale Study of Antibody Titer Decay Following BNT162b2 MRNA Vaccine or SARS-CoV-2 Infection</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10010064</pub-id></element-citation></ref><ref id="B30-vaccines-12-01358"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x02019;Huillier</surname><given-names>A.G.</given-names></name>
<name><surname>Meyer</surname><given-names>B.</given-names></name>
<name><surname>Andrey</surname><given-names>D.O.</given-names></name>
<name><surname>Arm-Vernez</surname><given-names>I.</given-names></name>
<name><surname>Baggio</surname><given-names>S.</given-names></name>
<name><surname>Didierlaurent</surname><given-names>A.</given-names></name>
<name><surname>Eberhardt</surname><given-names>C.S.</given-names></name>
<name><surname>Eckerle</surname><given-names>I.</given-names></name>
<name><surname>Grasset-Salomon</surname><given-names>C.</given-names></name>
<name><surname>Huttner</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Antibody Persistence in the First 6 Months Following SARS-CoV-2 Infection among Hospital Workers: A Prospective Longitudinal Study</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><fpage>784.e1</fpage><lpage>784.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.01.005</pub-id></element-citation></ref><ref id="B31-vaccines-12-01358"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>A.</given-names></name>
<name><surname>Muecksch</surname><given-names>F.</given-names></name>
<name><surname>Schaefer-Babajew</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Finkin</surname><given-names>S.</given-names></name>
<name><surname>Gaebler</surname><given-names>C.</given-names></name>
<name><surname>Ramos</surname><given-names>V.</given-names></name>
<name><surname>Cipolla</surname><given-names>M.</given-names></name>
<name><surname>Mendoza</surname><given-names>P.</given-names></name>
<name><surname>Agudelo</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Anti-SARS-CoV-2 Receptor-Binding Domain Antibody Evolution after MRNA Vaccination</article-title><source>Nature</source><year>2021</year><volume>600</volume><fpage>517</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04060-7</pub-id><pub-id pub-id-type="pmid">34619745</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01358"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heinz</surname><given-names>F.X.</given-names></name>
<name><surname>Stiasny</surname><given-names>K.</given-names></name>
</person-group><article-title>Distinguishing Features of Current COVID-19 Vaccines: Knowns and Unknowns of Antigen Presentation and Modes of Action</article-title><source>npj Vaccines</source><year>2021</year><volume>6</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00369-6</pub-id><pub-id pub-id-type="pmid">34400651</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01358"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mulligan</surname><given-names>M.J.</given-names></name>
<name><surname>Lyke</surname><given-names>K.E.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Neuzil</surname><given-names>K.</given-names></name>
<name><surname>Raabe</surname><given-names>V.</given-names></name>
<name><surname>Bailey</surname><given-names>R.</given-names></name>
<name><surname>Swanson</surname><given-names>K.A.</given-names></name>
<etal/>
</person-group><article-title>Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2639-4</pub-id><pub-id pub-id-type="pmid">32785213</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01358"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graham</surname><given-names>S.P.</given-names></name>
<name><surname>McLean</surname><given-names>R.K.</given-names></name>
<name><surname>Spencer</surname><given-names>A.J.</given-names></name>
<name><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name>
<name><surname>Wright</surname><given-names>D.</given-names></name>
<name><surname>Ulaszewska</surname><given-names>M.</given-names></name>
<name><surname>Edwards</surname><given-names>J.C.</given-names></name>
<name><surname>Hayes</surname><given-names>J.W.P.</given-names></name>
<name><surname>Martini</surname><given-names>V.</given-names></name>
<name><surname>Thakur</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of the Immunogenicity of Prime-Boost Vaccination with the Replication-Deficient Viral Vectored COVID-19 Vaccine Candidate ChAdOx1 NCoV-19</article-title><source>npj Vaccines</source><year>2020</year><volume>5</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41541-020-00221-3</pub-id><pub-id pub-id-type="pmid">31908851</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01358"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryan</surname><given-names>F.J.</given-names></name>
<name><surname>Norton</surname><given-names>T.S.</given-names></name>
<name><surname>McCafferty</surname><given-names>C.</given-names></name>
<name><surname>Blake</surname><given-names>S.J.</given-names></name>
<name><surname>Stevens</surname><given-names>N.E.</given-names></name>
<name><surname>James</surname><given-names>J.</given-names></name>
<name><surname>Eden</surname><given-names>G.L.</given-names></name>
<name><surname>Tee</surname><given-names>Y.C.</given-names></name>
<name><surname>Benson</surname><given-names>S.C.</given-names></name>
<name><surname>Masavuli</surname><given-names>M.G.</given-names></name>
<etal/>
</person-group><article-title>Systems Immunology Study Comparing Innate and Adaptive Immune Responses in Adults to COVID-19 MRNA and Adenovirus Vectored Vaccines</article-title><source>Cell Rep. Med.</source><year>2023</year><volume>4</volume><fpage>100971</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.100971</pub-id><pub-id pub-id-type="pmid">36871558</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01358"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munro</surname><given-names>A.P.S.</given-names></name>
<name><surname>Janani</surname><given-names>L.</given-names></name>
<name><surname>Cornelius</surname><given-names>V.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Babbage</surname><given-names>G.</given-names></name>
<name><surname>Baxter</surname><given-names>D.</given-names></name>
<name><surname>Bula</surname><given-names>M.</given-names></name>
<name><surname>Cathie</surname><given-names>K.</given-names></name>
<name><surname>Chatterjee</surname><given-names>K.</given-names></name>
<name><surname>Dodd</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of Seven COVID-19 Vaccines as a Third Dose (Booster) Following Two Doses of ChAdOx1 NCov-19 or BNT162b2 in the UK (COV-BOOST): A Blinded, Multicentre, Randomised, Controlled, Phase 2 Trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2258</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02717-3</pub-id><pub-id pub-id-type="pmid">34863358</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01358"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Falsey</surname><given-names>A.R.</given-names></name>
<name><surname>Frenck</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name>
<name><surname>Walsh</surname><given-names>E.E.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Bailey</surname><given-names>R.</given-names></name>
<name><surname>Swanson</surname><given-names>K.A.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>1627</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2113468</pub-id><pub-id pub-id-type="pmid">34525276</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01358"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolszczak-Biedrzycka</surname><given-names>B.</given-names></name>
<name><surname>Bie&#x00144;kowska</surname><given-names>A.</given-names></name>
<name><surname>Cie&#x0015b;likiewicz</surname><given-names>B.</given-names></name>
<name><surname>Smoli&#x00144;ska-Fijo&#x00142;ek</surname><given-names>E.</given-names></name>
<name><surname>Biedrzycki</surname><given-names>G.</given-names></name>
<name><surname>Dorf</surname><given-names>J.</given-names></name>
</person-group><article-title>The Effect of the Third Dose of the BNT162b2 Vaccine on Anti-SARS-CoV-2 Spike Antibody Levels in Healthcare Workers with and without COVID-19 Infection</article-title><source>Ann. Med.</source><year>2023</year><volume>55</volume><fpage>722</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1080/07853890.2023.2182907</pub-id><pub-id pub-id-type="pmid">36820816</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01358"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kester</surname><given-names>K.E.</given-names></name>
<name><surname>Mckinney</surname><given-names>D.A.</given-names></name>
<name><surname>Tornieporth</surname><given-names>N.</given-names></name>
<name><surname>Ockenhouse</surname><given-names>C.F.</given-names></name>
<name><surname>Heppner</surname><given-names>D.G.</given-names></name>
<name><surname>Hall</surname><given-names>T.</given-names></name>
<name><surname>Krzych</surname><given-names>U.</given-names></name>
<name><surname>Delchambre</surname><given-names>M.</given-names></name>
<name><surname>Voss</surname><given-names>G.</given-names></name>
<name><surname>Dowler</surname><given-names>M.G.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against Experimental Plasmodium Falciparum Malaria</article-title><source>J. Infect. Dis.</source><year>2001</year><volume>183</volume><fpage>640</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1086/318534</pub-id><pub-id pub-id-type="pmid">11170991</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01358"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>M.T.</given-names></name>
<name><surname>Verity</surname><given-names>R.</given-names></name>
<name><surname>Griffi</surname><given-names>J.T.</given-names></name>
<name><surname>Asante</surname><given-names>K.P.</given-names></name>
<name><surname>Owusu-agyei</surname><given-names>S.</given-names></name>
<name><surname>Greenwood</surname><given-names>B.</given-names></name>
<name><surname>Drakeley</surname><given-names>C.</given-names></name>
<name><surname>Gesase</surname><given-names>S.</given-names></name>
<name><surname>Kremsner</surname><given-names>P.</given-names></name>
<name><surname>Hoff</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of the RTS, S/AS01 Malaria Vaccine and Implications for Duration of Vaccine Effi Cacy: Secondary Analysis of Data from a Phase 3 Randomised Controlled Trial</article-title><source>Lancet Infect. Dis.</source><year>2015</year><volume>15</volume><fpage>1450</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00239-X</pub-id><pub-id pub-id-type="pmid">26342424</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01358"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McNamara</surname><given-names>H.A.</given-names></name>
<name><surname>Idris</surname><given-names>A.H.</given-names></name>
<name><surname>Sutton</surname><given-names>H.J.</given-names></name>
<name><surname>Vistein</surname><given-names>R.</given-names></name>
<name><surname>Flynn</surname><given-names>B.J.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Wiehe</surname><given-names>K.</given-names></name>
<name><surname>Lyke</surname><given-names>K.E.</given-names></name>
<name><surname>Chatterjee</surname><given-names>D.</given-names></name>
<name><surname>KC</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response</article-title><source>Cell Host Microbe</source><year>2020</year><volume>28</volume><fpage>572</fpage><lpage>585.e7</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.07.001</pub-id><pub-id pub-id-type="pmid">32697938</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01358"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarnitsyna</surname><given-names>V.I.</given-names></name>
<name><surname>Ellebedy</surname><given-names>A.H.</given-names></name>
<name><surname>Davis</surname><given-names>C.</given-names></name>
<name><surname>Jacob</surname><given-names>J.</given-names></name>
<name><surname>Ahmed</surname><given-names>R.</given-names></name>
<name><surname>Antia</surname><given-names>R.</given-names></name>
</person-group><article-title>Masking of Antigenic Epitopes by Antibodies Shapes the Humoral Immune Response to Influenza</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2015</year><volume>370</volume><pub-id pub-id-type="doi">10.1098/rstb.2014.0248</pub-id></element-citation></ref><ref id="B43-vaccines-12-01358"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarnitsyna</surname><given-names>V.I.</given-names></name>
<name><surname>Lavine</surname><given-names>J.</given-names></name>
<name><surname>Ellebedy</surname><given-names>A.</given-names></name>
<name><surname>Ahmed</surname><given-names>R.</given-names></name>
<name><surname>Antia</surname><given-names>R.</given-names></name>
</person-group><article-title>Multi-Epitope Models Explain How Pre-Existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005692</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005692</pub-id><pub-id pub-id-type="pmid">27336297</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01358"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellebedy</surname><given-names>A.H.</given-names></name>
<name><surname>Krammer</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>G.-M.</given-names></name>
<name><surname>Miller</surname><given-names>M.S.</given-names></name>
<name><surname>Chiu</surname><given-names>C.</given-names></name>
<name><surname>Wrammert</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>C.Y.</given-names></name>
<name><surname>Davis</surname><given-names>C.W.</given-names></name>
<name><surname>McCausland</surname><given-names>M.</given-names></name>
<name><surname>Elbein</surname><given-names>R.</given-names></name>
</person-group><article-title>Induction of Broadly Cross-Reactive Antibody Responses to the Influenza HA Stem Region Following H5N1 Vaccination in Humans</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>13133</fpage><lpage>13138</lpage><pub-id pub-id-type="doi">10.1073/pnas.1414070111</pub-id><pub-id pub-id-type="pmid">25157133</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01358"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>R&#x000f6;ltgen</surname><given-names>K.</given-names></name>
<name><surname>Nielsen</surname><given-names>S.C.A.</given-names></name>
<name><surname>Silva</surname><given-names>O.</given-names></name>
<name><surname>Younes</surname><given-names>S.F.</given-names></name>
<name><surname>Zaslavsky</surname><given-names>M.</given-names></name>
<name><surname>Costales</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Wirz</surname><given-names>O.F.</given-names></name>
<name><surname>Solis</surname><given-names>D.</given-names></name>
<name><surname>Hoh</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group><article-title>Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS-CoV-2 Infection and Vaccination</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>1025</fpage><lpage>1040.e14</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.018</pub-id><pub-id pub-id-type="pmid">35148837</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01358"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Rocha Queiroz Lima</surname><given-names>M.</given-names></name>
<name><surname>Nogueira</surname><given-names>R.M.R.</given-names></name>
<name><surname>Nogueira</surname><given-names>R.M.R.</given-names></name>
<name><surname>Nunes</surname><given-names>P.C.G.</given-names></name>
<name><surname>de Sousa</surname><given-names>C.S.</given-names></name>
<name><surname>da Silva</surname><given-names>M.H.</given-names></name>
<name><surname>Santos</surname><given-names>F.B.D.</given-names></name>
</person-group><article-title>A Simple Heat Dissociation Method Increases Significantly the ELISA Detection Sensitivity of the Nonstructural-1 Glycoprotein in Patients Infected with DENV Type-4</article-title><source>J. Virol. Methods</source><year>2014</year><volume>204</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2014.02.031</pub-id><pub-id pub-id-type="pmid">24747585</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01358"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robert</surname><given-names>C.</given-names></name>
<name><surname>Bollinger</surname><given-names>J.R.</given-names></name>
<name><surname>Richard</surname><given-names>L.</given-names></name>
<name><surname>Kline</surname><given-names>H.L.</given-names></name>
<name><surname>Francis</surname><given-names>M.W.</given-names></name>
<name><surname>Moss</surname><given-names>J.G.</given-names></name>
<name><surname>Bartlett</surname><given-names>T.C.Q.</given-names></name>
</person-group><article-title>Acid Dissociation Increases the Sensitivity of P24 Antigen Detection for the Evaluation of Antiviral Therapy and Disease Progression in Asymptomatic Human Immunodeficiency Virus-Infected Persons</article-title><source>J. Infect. Dis.</source><year>1992</year><volume>165</volume><fpage>913</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">1569343</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01358"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tas</surname><given-names>J.M.J.</given-names></name>
<name><surname>Koo</surname><given-names>J.H.</given-names></name>
<name><surname>Lin</surname><given-names>Y.C.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Steichen</surname><given-names>J.M.</given-names></name>
<name><surname>Jackson</surname><given-names>A.M.</given-names></name>
<name><surname>Hauser</surname><given-names>B.M.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Cottrell</surname><given-names>C.A.</given-names></name>
<name><surname>Torres</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Antibodies from Primary Humoral Responses Modulate the Recruitment of Naive B Cells during Secondary Responses</article-title><source>Immunity</source><year>2022</year><volume>55</volume><fpage>1856</fpage><lpage>1871.e6</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.07.020</pub-id><pub-id pub-id-type="pmid">35987201</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01358"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schaefer-Babajew</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Muecksch</surname><given-names>F.</given-names></name>
<name><surname>Cho</surname><given-names>A.</given-names></name>
<name><surname>Loewe</surname><given-names>M.</given-names></name>
<name><surname>Cipolla</surname><given-names>M.</given-names></name>
<name><surname>Raspe</surname><given-names>R.</given-names></name>
<name><surname>Johnson</surname><given-names>B.</given-names></name>
<name><surname>Canis</surname><given-names>M.</given-names></name>
<name><surname>DaSilva</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Antibody Feedback Regulates Immune Memory after SARS-CoV-2 MRNA Vaccination</article-title><source>Nature</source><year>2023</year><volume>613</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05609-w</pub-id><pub-id pub-id-type="pmid">36473496</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01358"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dangi</surname><given-names>T.</given-names></name>
<name><surname>Sanchez</surname><given-names>S.</given-names></name>
<name><surname>Lew</surname><given-names>M.H.</given-names></name>
<name><surname>Awakoaiye</surname><given-names>B.</given-names></name>
<name><surname>Visvabharathy</surname><given-names>L.</given-names></name>
<name><surname>Richner</surname><given-names>J.M.</given-names></name>
<name><surname>Koralnik</surname><given-names>I.J.</given-names></name>
<name><surname>Penaloza-MacMaster</surname><given-names>P.</given-names></name>
</person-group><article-title>Pre-Existing Immunity Modulates Responses to MRNA Boosters</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112167</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112167</pub-id><pub-id pub-id-type="pmid">36857186</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01358"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parry</surname><given-names>H.</given-names></name>
<name><surname>Bruton</surname><given-names>R.</given-names></name>
<name><surname>Stephens</surname><given-names>C.</given-names></name>
<name><surname>Bentley</surname><given-names>C.</given-names></name>
<name><surname>Brown</surname><given-names>K.</given-names></name>
<name><surname>Amirthalingam</surname><given-names>G.</given-names></name>
<name><surname>Hallis</surname><given-names>B.</given-names></name>
<name><surname>Otter</surname><given-names>A.</given-names></name>
<name><surname>Zuo</surname><given-names>J.</given-names></name>
<name><surname>Moss</surname><given-names>P.</given-names></name>
</person-group><article-title>Extended Interval BNT162b2 Vaccination Enhances Peak Antibody Generation</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00432-w</pub-id><pub-id pub-id-type="pmid">35087066</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01358"><label>52.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>INSPQ</collab>
</person-group><article-title>Efficacit&#x000e9; de Deux Doses de Vaccin Contre La COVID-9 Chez Les Adultes Qu&#x000e9;b&#x000e9;cois Vivant Dans La Communaut&#x000e9;</article-title><comment>Available online: <ext-link xlink:href="https://www.inspq.qc.ca/covid-19/vaccination/efficacite-2-doses" ext-link-type="uri">https://www.inspq.qc.ca/covid-19/vaccination/efficacite-2-doses</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-12-02">(accessed on 2 December 2021)</date-in-citation></element-citation></ref><ref id="B53-vaccines-12-01358"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delaunay</surname><given-names>C.L.</given-names></name>
<name><surname>Melo</surname><given-names>A.</given-names></name>
<name><surname>Maurel</surname><given-names>M.</given-names></name>
<name><surname>Mazagatos</surname><given-names>C.</given-names></name>
<name><surname>Goerlitz</surname><given-names>L.</given-names></name>
<name><surname>O&#x02019;Donnell</surname><given-names>J.</given-names></name>
<name><surname>Oroszi</surname><given-names>B.</given-names></name>
<name><surname>S&#x000e8;ve</surname><given-names>N.</given-names></name>
<name><surname>Rodrigues</surname><given-names>A.P.</given-names></name>
<name><surname>Mart&#x000ed;nez-Baz</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023&#x02013;January 2024</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>3931</fpage><lpage>3937</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.05.067</pub-id><pub-id pub-id-type="pmid">38839521</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01358"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Begovac</surname><given-names>J.</given-names></name>
</person-group><article-title>First real-life data on COVID-19 vaccine effectiveness against hospitalisation and severe disease from the eastern part of the WHO European Region</article-title><source>Lancet Reg. Health-Eur.</source><year>2024</year><volume>47</volume><fpage>101130</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2024.101130</pub-id><pub-id pub-id-type="pmid">39559480</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01358"><label>55.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>COVID-19 Epidemiological Update-6 November 2024</source><edition>173rd ed.</edition><publisher-name>WHO</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-173" ext-link-type="uri">https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-173</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-25">(accessed on 25 November 2024)</date-in-citation></element-citation></ref><ref id="B56-vaccines-12-01358"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takei</surname><given-names>S.</given-names></name>
<name><surname>Ai</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Igawa</surname><given-names>G.</given-names></name>
<name><surname>Kanno</surname><given-names>T.</given-names></name>
<name><surname>Tobiume</surname><given-names>M.</given-names></name>
<name><surname>Hiki</surname><given-names>M.</given-names></name>
<name><surname>Saito</surname><given-names>K.</given-names></name>
<name><surname>Khasawneh</surname><given-names>A.</given-names></name>
<name><surname>Wakita</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Performance Evaluation of the Roche Elecsys<sup>&#x000ae;</sup> Anti-SARS-CoV-2 Immunoassays by Comparison with Neutralizing Antibodies and Clinical Assessment</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0274181</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0274181</pub-id><pub-id pub-id-type="pmid">36107911</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01358"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taffertshofer</surname><given-names>K.</given-names></name>
<name><surname>Walter</surname><given-names>M.</given-names></name>
<name><surname>Mackeben</surname><given-names>P.</given-names></name>
<name><surname>Kraemer</surname><given-names>J.</given-names></name>
<name><surname>Potapov</surname><given-names>S.</given-names></name>
<name><surname>Jochum</surname><given-names>S.</given-names></name>
</person-group><article-title>Design and Performance Characteristics of the Elecsys Anti-SARS-CoV-2 S Assay</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1002576</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1002576</pub-id><pub-id pub-id-type="pmid">36532081</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01358-f001"><label>Figure 1</label><caption><p>Graphical representation of the prospective cohort study with timepoints of vaccine administration and number of participants at each timepoint.</p></caption><graphic xlink:href="vaccines-12-01358-g001" position="float"/></fig><fig position="float" id="vaccines-12-01358-f002"><label>Figure 2</label><caption><p>Serology profiles across timepoints. The top row are boxplots of serological data, and bottom row show geometric means (+/&#x02212; 1 standard deviation); AZ = AstraZeneca; T0 = baseline (first vaccine); T1 = second vaccine shot (except Post-COVID group), which is 3 weeks and 3 months after T0 for the Pfizer (T1a) and AZ (T1b) groups, respectively; T1 + 1M = T1 + 1 month to baseline; T1 + 4M = T1 + 4 months to baseline; T1 + 8M = T1 + 8 months to baseline (only Pfizer group); Booster = third dose. For the Post-COVID group, T1 + 1M~T0 + 1M and T1 + 4M~T0 + 4M.</p></caption><graphic xlink:href="vaccines-12-01358-g002" position="float"/></fig><fig position="float" id="vaccines-12-01358-f003"><label>Figure 3</label><caption><p>The serological profiles of participants across time, where time zero (T0) is the baseline.</p></caption><graphic xlink:href="vaccines-12-01358-g003" position="float"/></fig><table-wrap position="float" id="vaccines-12-01358-t001"><object-id pub-id-type="pii">vaccines-12-01358-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AZ<break/>(<italic toggle="yes">n</italic> = 68)<break/>Median<break/>(N)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AZ<break/>(<italic toggle="yes">n</italic> = 68)<break/>Range<break/>(%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pfizer<break/>(<italic toggle="yes">n</italic> = 51)<break/>Median<break/>(N)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pfizer<break/>(<italic toggle="yes">n</italic> = 51)<break/>%<break/>(Range)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-COVID (<italic toggle="yes">n</italic> = 72)<break/>Median<break/>(N)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-COVID<break/>(<italic toggle="yes">n</italic> = 72)<break/>%<break/>(Range)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Difference <break/><italic toggle="yes">p</italic>-Value ****</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.5</td><td align="center" valign="middle" rowspan="1" colspan="1">20&#x02013;66</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">24&#x02013;65</td><td align="center" valign="middle" rowspan="1" colspan="1">44</td><td align="center" valign="middle" rowspan="1" colspan="1">20&#x02013;68</td><td align="center" valign="middle" rowspan="1" colspan="1">0.968</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">88.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">76.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">84.7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.218</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Serology time diff. (days)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pre-baseline * to baseline (T0) </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;118</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;118&#x02013;&#x02212;118</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1a (3 weeks) to baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">23&#x02013;23</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1b (3 months) to baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">84</td><td align="center" valign="middle" rowspan="1" colspan="1">84&#x02013;84</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1 + 1 month to baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">123</td><td align="center" valign="middle" rowspan="1" colspan="1">120&#x02013;123</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td><td align="center" valign="middle" rowspan="1" colspan="1">51&#x02013;51</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">36&#x02013;36</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1 + 4 months to baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">214</td><td align="center" valign="middle" rowspan="1" colspan="1">214&#x02013;221</td><td align="center" valign="middle" rowspan="1" colspan="1">147</td><td align="center" valign="middle" rowspan="1" colspan="1">147&#x02013;147</td><td align="center" valign="middle" rowspan="1" colspan="1">118</td><td align="center" valign="middle" rowspan="1" colspan="1">118&#x02013;118</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1a + 8 months to baseline **</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">266</td><td align="center" valign="middle" rowspan="1" colspan="1">266&#x02013;267</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000b7;&#x000b7;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Booster *** to baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">286</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">267&#x02013;328</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">310</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">303&#x02013;366</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">183</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">176&#x02013;239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>AZ = AstraZeneca; T0 = first vaccine shot (baseline); T1 = second vaccine shot (except Post-COVID group); * blood collected 4 months before vaccination (only Post-COVID group); ** 8 months (only Pfizer group); *** there was incomplete sampling at the booster timepoint (number with serology: AZ 40/68; Pfizer 32/51; Post-COVID 40/72); note that T1 + 1 (4) months can be considered ~T0 + 1 (4) months for the Post-COVID group; **** all Kruskal&#x02013;Wallis tests, except for gender (Chi-Sq).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01358-t002"><object-id pub-id-type="pii">vaccines-12-01358-t002_Table 2</object-id><label>Table 2</label><caption><p>Serological profiles across timepoints.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Timepoint</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Median</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IQR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Geom. <break/>Mean (SD)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fold Change in Geom. Mean [Trend] </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZ</td><td align="center" valign="middle" rowspan="1" colspan="1">T0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.400</td><td align="center" valign="middle" rowspan="1" colspan="1">0.400&#x02013;0.400</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60 (3.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline [-]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1b *</td><td align="center" valign="middle" rowspan="1" colspan="1">72.57</td><td align="center" valign="middle" rowspan="1" colspan="1">22.08&#x02013;173.65</td><td align="center" valign="middle" rowspan="1" colspan="1">69.33 (5.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">116.23 [&#x0003e;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1b + 1 month</td><td align="center" valign="middle" rowspan="1" colspan="1">1197</td><td align="center" valign="middle" rowspan="1" colspan="1">592.35&#x02013;1963.6</td><td align="center" valign="middle" rowspan="1" colspan="1">878.80 (4.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.68 [&#x0003e;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1b + 4 months</td><td align="center" valign="middle" rowspan="1" colspan="1">550.8</td><td align="center" valign="middle" rowspan="1" colspan="1">234.7&#x02013;1200.2</td><td align="center" valign="middle" rowspan="1" colspan="1">507.28 (6.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58 [&#x0003c;]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Booster</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,846</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9042.5&#x02013;24,554.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,251.21 (5.87)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.21 [&#x0003e;] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer</td><td align="center" valign="middle" rowspan="1" colspan="1">T0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.400</td><td align="center" valign="middle" rowspan="1" colspan="1">0.400&#x02013;0.400</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 (3.48) </td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline [-]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1a *</td><td align="center" valign="middle" rowspan="1" colspan="1">93.09</td><td align="center" valign="middle" rowspan="1" colspan="1">36.84&#x02013;250</td><td align="center" valign="middle" rowspan="1" colspan="1">80.17 (3.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">139.95 [&#x0003e;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1a + 1 month</td><td align="center" valign="middle" rowspan="1" colspan="1">2441.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1564&#x02013;4030</td><td align="center" valign="middle" rowspan="1" colspan="1">2332.60 (2.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">29.10 [&#x0003e;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1a + 4 months</td><td align="center" valign="middle" rowspan="1" colspan="1">1294.0</td><td align="center" valign="middle" rowspan="1" colspan="1">824.4&#x02013;1874</td><td align="center" valign="middle" rowspan="1" colspan="1">1145.33 (2.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.49 [&#x0003c;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1a + 8 months</td><td align="center" valign="middle" rowspan="1" colspan="1">737.3</td><td align="center" valign="middle" rowspan="1" colspan="1">463.5&#x02013;1265.2</td><td align="center" valign="middle" rowspan="1" colspan="1">754.91 (2.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66 [&#x0003c;]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Booster</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,220&#x02013;25,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18,923.95 (1.45)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.07 [&#x0003e;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Post-COVID</td><td align="center" valign="middle" rowspan="1" colspan="1">4 months pre-T0</td><td align="center" valign="middle" rowspan="1" colspan="1">84.95</td><td align="center" valign="middle" rowspan="1" colspan="1">36.77&#x02013;213.85</td><td align="center" valign="middle" rowspan="1" colspan="1">79.45 (4.70)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T0</td><td align="center" valign="middle" rowspan="1" colspan="1">97.86</td><td align="center" valign="middle" rowspan="1" colspan="1">46.79&#x02013;192.43</td><td align="center" valign="middle" rowspan="1" colspan="1">92.01 (3.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline [-]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1 ** + 1 month</td><td align="center" valign="middle" rowspan="1" colspan="1">11703</td><td align="center" valign="middle" rowspan="1" colspan="1">9406&#x02013;21,368</td><td align="center" valign="middle" rowspan="1" colspan="1">12,977.29 (1.73)</td><td align="center" valign="middle" rowspan="1" colspan="1">141.04 [&#x0003e;]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">T1 ** + 4 months</td><td align="center" valign="middle" rowspan="1" colspan="1">4610</td><td align="center" valign="middle" rowspan="1" colspan="1">3008.8&#x02013;8450</td><td align="center" valign="middle" rowspan="1" colspan="1">4920.43 (2.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38 [&#x0003c;]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Booster</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,264</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6111&#x02013;15,552</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9702.92 (1.90) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.97 [&#x0003e;]</td></tr></tbody></table><table-wrap-foot><fn><p>IQR = inter-quartile range; Geom. = geometric; SD standard deviation; AZ AstraZeneca (n = 68), Pfizer (n = 51), Post-COVID (n = 72); T0 = baseline (first vaccine shot); * T1 = second vaccine shot (except Post-COVID group), which is 3 weeks and 3 months after T0 for Pfizer (T1a) and AZ (T1b) groups, respectively; ** note that T1 + 1 (4) month(s) can be considered ~T0 + 1 (4) month(s) for the Post-COVID group; there was incomplete sampling at the booster timepoint (number with serology: AZ 40/68; Pfizer 32/51; Post-COVID 40/72).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01358-t003"><object-id pub-id-type="pii">vaccines-12-01358-t003_Table 3</object-id><label>Table 3</label><caption><p>Serology measures compared to the T1 + 1-month (T1 + 1M) timepoint.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Timepoint Ratio (/T1 + 1M)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Median</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IQR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean (SD)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Difference <italic toggle="yes">p</italic>-Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">T0</td><td align="center" valign="middle" rowspan="1" colspan="1">AZ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002&#x02013;0.0016</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0057 (0.0263)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;10<sup>&#x02212;15</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T0</td><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001&#x02013;0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005 (0.0010)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-COVID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0078</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0045&#x02013;0.0166</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0115 (0.0106)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1 + 4M</td><td align="center" valign="middle" rowspan="1" colspan="1">AZ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3185&#x02013;0.5172 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.4170 (0.1623) </td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0033</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T1 + 4M</td><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5402</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3517&#x02013;0.6536 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.5283 (0.1971)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T1 + 4M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-COVID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3645</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2903&#x02013;0.4905</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4045 (0.1770)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Booster</td><td align="center" valign="middle" rowspan="1" colspan="1">AZ</td><td align="center" valign="middle" rowspan="1" colspan="1">12.924</td><td align="center" valign="middle" rowspan="1" colspan="1">7.812&#x02013;27.356 </td><td align="center" valign="middle" rowspan="1" colspan="1">22.165 (27.088)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;10<sup>&#x02212;15</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Booster</td><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8852</td><td align="center" valign="middle" rowspan="1" colspan="1">5.942&#x02013;10.484 </td><td align="center" valign="middle" rowspan="1" colspan="1">9.759 (6.612)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Booster</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-COVID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8558</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5752&#x02013;1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8787 (0.4360)</td></tr></tbody></table><table-wrap-foot><fn><p>IQR = inter-quartile range; AZ = AstraZeneca; * Kruskal&#x02014;Wallis test; T0 = Baseline (first vaccine shot); T1 = second vaccine shot (except Post-COVID group), which is 3 weeks and 3 months after T0 for the Pfizer (T1a) and AZ (T1b) groups, respectively (see <xref rid="vaccines-12-01358-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-12-01358-t002" ref-type="table">Table 2</xref>); T1 + 1M = T1 + 1 month to baseline; T1 + 4M = T1 + 4 months to baseline; Booster = third dose. For the Post-COVID group, T1 + 1M~T0 + 1M and T1 + 4M~T0 + 4M; there was incomplete sampling at the booster timepoint (number with serology: AZ 40/68; Pfizer 32/51; Post-COVID 40/72).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01358-t004"><object-id pub-id-type="pii">vaccines-12-01358-t004_Table 4</object-id><label>Table 4</label><caption><p>Linear mixed model of (log) serological assay values across timepoints.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fixed Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Estimate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LCL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">UCL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Intercept</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6716</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1743</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1689</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0088</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0083</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0183</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0018</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1103</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male vs. female</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0152</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3083</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3386</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9270</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1 + 1M vs. T0</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5991</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3190</td><td align="center" valign="middle" rowspan="1" colspan="1">6.8793</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1 + 4M vs. T0</td><td align="center" valign="middle" rowspan="1" colspan="1">6.0483</td><td align="center" valign="middle" rowspan="1" colspan="1">5.7734</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3232</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Booster vs. T0</td><td align="center" valign="middle" rowspan="1" colspan="1">9.2521</td><td align="center" valign="middle" rowspan="1" colspan="1">8.9481</td><td align="center" valign="middle" rowspan="1" colspan="1">9.5560</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pfizer vs. AZ</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0336</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3337</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8578</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Post-COVID vs. AZ</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1967</td><td align="center" valign="middle" rowspan="1" colspan="1">3.8421</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5512</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1 + 1M &#x000d7; Pfizer *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8963</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4972</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2955</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1 + 4M &#x000d7; Pfizer *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7621</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3607</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1635</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00023</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Booster &#x000d7; Pfizer *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3556</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0918</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1200</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1 + 1M &#x000d7; Post-COVID *</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.6839</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0763</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2916</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;7 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1 + 4M &#x000d7; Post-COVID *</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0898</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4749</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.7047</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Booster &#x000d7; Post-COVID *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.6049</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.0305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.1793</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr></tbody></table><table-wrap-foot><fn><p>AZ = AstraZeneca; T0 baseline; T1 + 1M = T1 + 1 month to baseline; T1 + 4M = T1 + 4 months to baseline; Booster = third dose. For the Post-COVID group, T1 + 1M~T0 + 1M and T1 + 4M~T0 + 4M. LCL, lower 95% confidence interval, UCL, upper 95% confidence interval; * interaction effects.</p></fn></table-wrap-foot></table-wrap></floats-group></article>